Onsdag 30 Oktober | 09:27:24 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2025-05-20 09:00 Kvartalsrapport 2025-Q1
2025-05-20 - Årsstämma
2025-02-25 08:00 Bokslutskommuniké 2024
2024-11-19 09:00 Kvartalsrapport 2024-Q3
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-22 - X-dag ordinarie utdelning SYNT 0.00 SEK
2024-05-21 - Årsstämma
2024-05-21 - Kvartalsrapport 2024-Q1
2024-02-20 - Extra Bolagsstämma 2024
2024-02-20 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-22 - Kvartalsrapport 2023-Q2
2023-05-24 - X-dag ordinarie utdelning SYNT 0.00 SEK
2023-05-23 - Årsstämma
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning SYNT 0.00 SEK
2022-05-10 - Kvartalsrapport 2022-Q1
2022-05-10 - Årsstämma
2022-03-29 - Extra Bolagsstämma 2022
2022-02-22 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-07-13 - Kvartalsrapport 2021-Q2
2021-05-20 - Split SYNT 1:10
2021-05-12 - X-dag ordinarie utdelning SYNT 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-10-02 - X-dag ordinarie utdelning SYNT 1.50 SEK
2020-07-14 - Kvartalsrapport 2020-Q2
2020-05-05 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-07-14 - Kvartalsrapport 2019-Q2
2019-04-30 - X-dag ordinarie utdelning SYNT 1.50 SEK
2019-04-29 - Kvartalsrapport 2019-Q1
2019-04-29 - Årsstämma
2019-02-27 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-04-26 - X-dag ordinarie utdelning SYNT 0.00 SEK
2018-04-25 - Kvartalsrapport 2018-Q1
2018-04-25 - Årsstämma
2018-02-21 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-26 - X-dag ordinarie utdelning SYNT 0.00 SEK
2017-04-25 - Årsstämma
2017-04-25 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2016-10-28 - Kvartalsrapport 2016-Q3
2016-08-26 - Kvartalsrapport 2016-Q2
2016-04-27 - X-dag ordinarie utdelning SYNT 0.00 SEK
2016-04-26 - Årsstämma
2016-04-26 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-04-13 - Årsstämma
2015-04-13 - Kvartalsrapport 2015-Q1
2015-02-17 - X-dag ordinarie utdelning SYNT 0.00 SEK
2015-02-13 - Bokslutskommuniké 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-09-26 - Extra Bolagsstämma 2014
2014-08-29 - Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
SyntheticMR är ett medicinteknik-bolag som är verksamt inom utveckling av analys - och avbildningsmetoder. Tekniken används huvudsakligen för magnetisk resonanstomografi (MR) inom sjukvården. Tekniken baseras på kvantifieringsbaserad metod som ämnar öka effektiviteten och kvalitén i nuvarande MR-undersökningar. Bolaget etablerades under 2007 och har sitt huvudkontor i Linköping.
2024-03-12 18:12:40

At the extraordinary general meeting on February 20, 2024, it was decided to introduce the incentive program LTIP 2024 for personnel in Sweden within SyntheticMR AB (publ) (hereinafter referred to as the "Company"), as well as the possibility to subscribe to customary warrants of series TO 2. Furthermore, it was decided on TO 3 involving an opportunity for an employee in the USA to subscribe for warrants of series TO 3. LTIP 2024 gives employees of the Company the opportunity to subscribe for shares, with attached share rights, at the market value in a directed issue. The board of the Company has now decided on the allocation of the shares and warrants of series TO 2.

LTIP 2024
In accordance with the terms, the subscription price for shares in the directed issue has previously been set at SEK 25.04 per share. A total of 15 subscribers are allocated 37,500 shares in the Company. Through the directed issue, approximately SEK 0.9 million will be added to the Company. At the same time, 75,000 warrants are issued to the Company for safekeeping until the exercise period begins in three years. Time for payment regarding allocated shares lasts until March 27, 2024.

TO 2
In accordance with the conditions, the rate for subscribing to TO 2 was previously set at SEK 6.34 per warrant. Fixed price for use of TO 2 after three years amounts to SEK 28.80 per share. In total, 40,000 TO 2 in the Company were subscribed and the Company is thus infused with approximately SEK 0.25 million. Time for payment lasts until March 27, 2024. Provided that all TO 2 are used (in three years' time), the Company will receive an additional SEK 1.1 million.

Number of shares and dilution
As a result of LTIP 2024, the number of shares in the Company, after registration with the Swedish Companies Registration Office, will initially increase by 37,500 shares, to a total of 41,688,280 shares. The share capital increases at the same time by an initial SEK 832.5, to a total of SEK 925,479.816. After the end of the term in three years, the number of shares, upon full use of the warrants issued to the Company for technical reasons, can increase by an additional 75,000 shares, to a total 41,763,280 shares. At the same time, if these warrants are fully exercised, the share capital can increase by 1,665 SEK, to a total of 927,144.816 SEK. The total dilution as a result of LTIP 2024 thus amounts to approximately 0.27 percent of votes and capital.

As a result of TO 2, the total number of shares in the Company, upon full use of all TO 2 after three years, can increase by an additional 40,000 shares, to a total of 41,803,280 shares. The share capital then increases at the same time by 888 SEK, to a total of 928,032.816 SEK. The total dilution as a result of TO 2 thus amounts to an additional 0.10 percent of votes and capital. All the figures stated above are calculated on the basis that warrants issued in connection with LTIP 2024 are fully used.

For further information, please contact Ulrik Harrysson, CEO of SyntheticMR AB (publ).

Phone: +46 70 529 29 87

E-mail: ulrik.harrysson@syntheticmr.com.